The study aims to identify immune biomarkers in peripheral blood for identifying Alzheimer's disease (AD). Blood samples from subjects with AD will be compared to age-matched controls without cognitive symptoms, as well as healthy younger subjects.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Frequency of monoclonal antibodies and of CD4+ and CD25+ T cells
Timeframe: Up to one year